[Fetal risks related to the administration of anti-arrhythmia drugs during pregnancy].
The major concern about the administration of antiarrhythmic drugs during pregnancy is related to their effect on fetal well-being. Even if teratogenic risks are higher during organogenesis in the first 8 weeks of pregnancy, after this period undesirable effects may include depression of uterine blood flow, interference with fetal growth and development, and interference with labor and delivery. Most drugs are secreted in the mother's milk, a fact that raises concern about the nursing infants. In this report we review the fetal risks related to the management of maternal arrhythmias during pregnancy showing that most patients can be treated with an excellent result for their babies.
Ferrero
Simone
S
Dipartimento di Ginecologia e Ostetricia Ospedale San Martino Padiglione 1 Largo R. Benzi, 10 16132 Genova. simoneferrero@libero.it
Colombo
Barbara M
BM
Arena
Elisa
E
Fenini
Fabio
F
Ragni
Nicola
N
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000328:Adult; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D001942:Breast Feeding; D018849:Controlled Clinical Trials as Topic; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced; D005333:Fetus / Q000187:drug effects*; D006801:Humans; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy*; D011261:Pregnancy Trimester, First; D011263:Pregnancy Trimester, Third; D018570:Risk Assessment
D000889:Anti-Arrhythmia Agents